-
Lilly's fast-acting insulin Lyumjev has been approved by the FDA
Time of Update: 2021-03-02
yesterday, Lilly announced that the FDA has approved its new type of meal-time insulin Lyumjev (insulin lispro-aabc, 100 units/mL and 200 units/mL) to improve blood sugar control in adult patients with type 1 and type 2 diabetes.
-
All four trials of the No. and Nord agitant Weight Loss Phase III STEP project were successful
Time of Update: 2021-03-02
The trial reached two main endpoints, with statistically significant differences: , the main statistical method showing that after 68 weeks of treatment in all randomized patients, the SC Semaglutide 2.4mg-IBT treatment group dropped 16.0% from an average baseline weight of 105.8 kg, and the placebo-IBT group lost 5.7% of its body weight.
-
China's new coronavirus vaccine Phase 1 clinical trials have achieved positive results
Time of Update: 2021-03-02
Chinese research team reported in the British medical journal The Lancet on the 22nd that they have conducted a phase 1 clinical trial of a new coronavirus vaccine, which has been shown to be safe and can induce rapid immune response.
-
Takeda Entervio under-skin preparations are available in China
Time of Update: 2021-03-02
As mentioned earlier, on December 20, 2019, the Company received a Full Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding a Biological Products Licensing Application (BLA) filed by the Company for the maintenance of entervio SC preparations for the treatment of adult patients with moderate to severe ulcerative colitis (UC).
-
The TCR-T research and development project of Xiang Xue Pharmaceuticals has been approved for clinical trials of the drug in the United States
Time of Update: 2021-03-02
TCRT-ESO-A2's approval for a new U.S. drug clinical trial is a phased result of TCR-T's new drug development, and it is not expected that the application for a license for this clinical trial will have a significant impact on the company's 2020 results.
-
AbbVie Skyrizi may gain more market share
Time of Update: 2021-03-02
In a report to clients, Geoffrey Porges, an analyst at US investment bank SVB Leerink, cites a medaCorp survey that suggests dermatologists tend to shift psoriasis patients from old drugs such as Otezla to new biologics, most notably AbbVie's latest Skyrizi.
-
Neuroblastoma in the UK is seeing the development of potential new therapies
Time of Update: 2021-03-02
the treatment, which blocks N-Myc activity by shutting down gene production, is expected to conduct a clinical trial in children with high-risk neuroblastoma by the end of 2020.
-
5th lung cancer adaptation! FDA approves Roche Tecentriq
Time of Update: 2021-03-02
This is a randomized, open-label Phase III study conducted in patients with advanced non-scaly or squamous non-small cell lung cancer (NSCLC) selected from programmed death ligation 1 (PD-L1) biomarkers who have not previously received chemotherapy (chemotherapy initial treatment), without ALC or EGFR mutations (wild type, WT), to assess the efficacy and safety of Tecentriq as a single-drug therapy for first-line (initial) therapy and to compare with chemotherapy.
-
Tiantian Bio and Genexine announced that TJ107 has been approved for Clinical Phase 2 trials
Time of Update: 2021-03-02
Heavenly Creatures (the "Company") , a clinically focused biopharmace companies in the field of tumor and autoimmune diseases, and Genexine Inc., a biopharmaceers company in the clinical stage dedicated to the development of innovative immunotherapy and new long-acting biologics, today announced that China's national The Drug Administration has approved the new long-acting recombinant human leukocyte interleukin 7 (rhIL-7) TJ107 / HyLeukin-7™ (Efineptakin alfa) to conduct Phase 2 clinical studies in newly diagnosed patients with glioblastoma with reduced lymphocytes.
-
Stone Pharmaceutical Group's application for the listing of anticancer drugs is to be included in the priority review
Time of Update: 2021-03-02
Recently, China's State Drug Administration Drug Review Center (CDE) website published information that Shi Pharmaceutical Group, China No. 1 Pharmaceuticals submitted the "hydrochloric acid mitochondrial lipid body injection" listing application is to be included in the priority review, on the grounds that "qualified drugs approved." The drug is applied for in patients with relapsed or incurable external T-cell lymphoma (PTCL).
-
Peppa Opdivo has shown an advantage in esophageal cancer
Time of Update: 2021-03-02
“ These results make esophageal and gastroesophageal cancer the second type of cancer after melanoma, where Opdivo has shown benefits in adpothesic therapy, suggesting that Opdivo may be the new standard of treatment for these patients.
-
Vertex's innovative triple therapy Kaftrio has been approved by the European Union
Time of Update: 2021-03-02
recently announced that Vertex Pharmaceuticals has announced that the European Commission (EC) has approved kaftrio(ivacaftor/tezacaftor/elexacaftor) and Kalydeco (ivacaftor) 150mg joint drug treatment for age ≥ 12-year-old CF patients, specifically: patients with an F508del mutation and a minimal functional mutation (F/MF) in the cystic fibrosis transfilm conductivity regulator (CFTR) gene, or 2 patients with an F508del mutation (F/F).
-
The FDA revoked the emergency use authorization for the treatment of COVID-19 with chloroquine and hydroxychloroquine
Time of Update: 2021-03-02
, the U.S. Food and Drug Administration (FDA) issued a statement revoking the Emergency Use Authorization (EUA) for the treatment of COVID-19 hospitalized patients.
-
Pfizer's Ibrace failed an early-stage breast cancer trial
Time of Update: 2021-03-02
The results came from the PENELOPE-B III clinical trial, which evaluated Palbociclib surgical chemotherapy in women with Hollyoos positive (HR plus), human epithelial growth factor negative (HER2-) early breast cancer, and pre-immersion residual immersion disease.
-
Bayer's first sGC stimulant filed for listing in China
Time of Update: 2021-03-02
The results showed that the study reached the primary therapeutic endpoint: a 10 mg dose per day compared to a placebo when combined with available heart failure drugs significantly reduced the compound risk of heart failure hospitalization and cardiovascular death after worsening events by 10% (relative risk reduction: HR 0.90, 95% CI: 0.82-0.98, p-0.019); This effect is consistent in most pre-specified subgroups, including patients who accept or do not accept Entresto (sacubitril/valsartan, shakab querzatan).
-
Ganley Pharmaceuticals has submitted an application for a U.S. clinical trial of NASH's new drug ASC42
Time of Update: 2021-03-02
Pharmaceutical Co., Ltd. today announced that it has submitted a clinical trial application (IND) for the non-alcoholic fatty hepatitis (NASH) candidate drug ASC42 to the FDA.
ASC41 is an oral thyroid hormone-infested (THR-thyroid) agitant whose NASH adaptation clinical trial application was recently approved by China's State Drug Administration.
-
Zeposia, a new drug for BSM multiple sclerosis, has been approved by the European Union
Time of Update: 2021-03-02
0.28); in the SUNBEAM study, the treatment was one year, compared to Avonex, Zepo Sia reduced the number of T1 weighted palaeum enhancement (GdE) brain injuries by 63% (0.16 vs 0.43) and the number of new or expanded T2 injuries by 48% (1.
-
Immunomedics' ADC drug Triple Negative Breast Cancer III was successful
Time of Update: 2021-02-28
April 6, Immunomedics announced the early termination of its Phase III ASCENT study on the treatment of metastasis triple-negative breast cancer (TNBC) with its ADC drug sacituzumab govitecan, as recommended by the Independent Data Monitoring Board.
-
Savara's Mogradex is eligible for the FDA's breakthrough drug
Time of Update: 2021-02-28
Rob Neville, CEO of Savara, said: "We are pleased that the FDA has awarded Molegradex a breakthrough drug qualification for the treatment of aPAP, a debilitating, rare lung disease that is not approved.
-
It's sunny and he's been approved for the first copy of the Nofowe film
Time of Update: 2021-02-28
China Biopharmaceutical said that there is currently no Entourturtent Nofowe tablet generic drug market, the original research imported products are expensive, greatly increase the cost of patients, it is difficult to have universal.
